Status:
COMPLETED
Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans
Lead Sponsor:
Medical University of Vienna
Conditions:
Imparied Retinal Vascular Reactivity
Healthy Subjects
Eligibility:
MALE
18-35 years
Phase:
NA
Brief Summary
Oxidative stress has been implicated to play a pathogenic role in many disease processes, especially in age-related disorders such as age-related macular degeneration. It has been hypothesized that an...
Eligibility Criteria
Inclusion
- Men aged between 18 and 35 years, nonsmokers
- Body mass index between 15th and 85th percentile (Must et al. 1991)
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropy \< 3 Dpt.
Exclusion
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug, vitamins and minerals supplements as well
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
- Blood donation during the previous 3 weeks
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02221089
Start Date
January 1 2013
End Date
July 1 2014
Last Update
August 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of clinical Pharmacology, Medical University of Vienna
Vienna, Vienna, Austria, 1080